ABSTRACT
Objective To study the protective effect of Xingnaojing combined with alprostadil on brain after acute ischemic stroke in rats.MethodsSixty patients with acute ischemic stroke were enrolled in zhejiang xin'an international hospital from March 2014 to March 2016.They were randomly divided into control group and treatment group, 30 cases in each group.The control group received conventional treatment plus alprostadil, the treatment group in the control group based on the combination of Xingnaojing treatment.Two groups of patients after treatment, are given nursing intervention, such as routine diet guidance, nutritional support, health education.The levels of serum oxidative stress (MDA), vascular endothelial growth factor (VEGF) and vascular endothelial growth factor (VEGF) were compared between the two groups before and after treatment.The levels of cerebral blood flow (CBFV) were recorded before and after treatment Observe the adverse reactions during treatment.ResultsAfter 14 days of treatment, the NIHSS score of the treatment group was lower than that of the control group and the ADL score was higher than that of the control group.The difference between the two groups was statistically significant (P<0.05).Before treatment, the oxidative stress indexes MDA and Hcy were no significant difference between the two groups.After treatment, the oxidative stress indexes MDA and Hcy were lower than the control group(P<0.05).Before treatment, the levels of VEGF and CBFV in the two groups were no significant difference between the two groups.After treatment, the levels of VEGF and CBFV in the two groups were significantly higher than those in the control group (P<0.05).The adverse reaction rate between the 2 groups was similar, and there was no significant adverse reaction, there was no significant difference between the two groups.ConclusionXingnaojing combined with alprostadil has a certain clinical effect on acute ischemic stroke, and has a good protective effect on brain tissue after reperfusion.
ABSTRACT
Objective: To study the protective effect of baicalin on myocardial ischemia reperfusion injury and its correlation to myocardial cell autophagy in experimental rats. Methods: The animal models were established by intragastric infusion at 7 days prior operation in different groups.Atotal of 48 rats were divided into 4 groups: Sham operation group, Sham+baicalin group, Ischemia reperfusion (IR) group and Baicalin treatment group. n=12 in each group. Hemodynamics at different time points and myocardial infarction (MI) size at 45 min after reperfusion were recorded; protein expressions of LC3-II and autophagy-related Becl-1 at 30 min after reperfusion were examined by Westernblot analysis; the opening condition of mitochondrial membrane channel transition pore (mPTP) was detected by NAD+ content. Results: The MI sizes in Sham operation group and Sham+baicalin group were too small to compare; MI sizes in IR group and Baicalin treatment group were (41.32±1.85) % vs (23.30±1.60) %, P<0.001. Protein expressions of LC3-II in IR group and Baicalin treatment group were (1.051±0.005) and (0.863±0.009) which were both higher than Sham operation group (0.763±0.007), P<0.01;Becl-1 were (1.169±0.002) and (0.943±0.005) which were both higher than Sham operation group (0.647±0.014),P<0.01; LC3-II and in Becl-1 expressions in Baicalin treatment group were decreased than IR group, P<0.01. NAD+ contents (by nmol/mg) in IR group and Baicalin treatment group were (6.02±0.33) and (9.56±0.53) which were both lower than Sham operation group (11.28±0.37), P<0.001; NAD+ content in Baicalin treatment group was increased than IR group,P<0.01. Conclusion: Baicalin had no autophagy effect in normal myocardial cells, but it may decrease the MI size and reduce excessive autophagy in myocardial cells after IR which might be related to inhibiting mPTP opening.
ABSTRACT
0.05); and in combined test,the combined ORe=1.94 (95% confidence interval ranged from 1.53 to 2.44,Z=5.58,P
ABSTRACT
OBJECTIVE:To evaluate the economic effects of three therapeutic schemes for chronic hepatitis B.METHODS:116 patients with chronic hepatitis B were divided into 3 groups:Group A(n=38) received lamivudine(100 mg?d-1,po) for 6 months;Group B(n=38) received IFN?-2b(3million IU?d-1,im) for 4 weeks followed by IFN?-2b(im,3million IU,qod);Group C(n=40) received IFN?-2b(3million IU?d-1,im) for 4 weeks followed by IFN?-2b(im,3million IU,qod) plus lamivudine(po,100 mg?d-1).The course of treatment for the three groups all lasted for 6 months.The cost-effectiveness of the three groups was evaluated using the principle of pharmacoeconomics.RESULTS:In A,B,and C groups,the costs were 3 420,12 168 and 15 588 Yuan,respectively,and the HBV-DNA negative changing rates were 44.7%,47.4% and 67.5%,respectively.The increment in cost for one more unit of effectiveness was 324 000.00 Yuan in Group B and 53 368.42 Yuan in Group C as compared with Group A.CONCLUSION:Scheme C is the optimal one pharmacoeconoically.